On October 21, 2024, Seaport Therapeutics, a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines, announced the completion of an oversubscribed $225 million Series B financing round. The funding was led by General Atlantic, a leading global growth investor, with participation from funds and accounts advised by T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also participated. Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction.

The additional capital will be used to advance Seaport’s clinical-stage pipeline of medications and its proprietary Glyph technology platform. The company's total capital now stands at $325 million since its launch in April 2024.

The Wilson Sonsini team that advised General Atlantic on patent matters related to the transaction includes Mike Hostetler, Minyoung Shin, and Jose Martinez.

For more information, please see media coverage from Biospace.